Effect of topical ophthalmic application of cidofovir on experimentally induced primary ocular feline herpesvirus-1 infection in cats

Jennifer P. Fontenelle Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523.

Search for other papers by Jennifer P. Fontenelle in
Current site
Google Scholar
PubMed
Close
 DVM
,
Cynthia C. Powell Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523.

Search for other papers by Cynthia C. Powell in
Current site
Google Scholar
PubMed
Close
 DVM, MS
,
Julia K. Veir Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523.

Search for other papers by Julia K. Veir in
Current site
Google Scholar
PubMed
Close
 DVM, PhD
,
Steven V. Radecki Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523.

Search for other papers by Steven V. Radecki in
Current site
Google Scholar
PubMed
Close
 PhD
, and
Michael R. Lappin Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523.

Search for other papers by Michael R. Lappin in
Current site
Google Scholar
PubMed
Close
 DVM, PhD

Abstract

Objective—To evaluate the efficacy of twice-daily ophthalmic application of 0.5% cidofovir solution in cats with experimentally induced primary ocular feline herpesvirus-1 (FHV-1) infection.

Animals—Twelve 6-month-old sexually intact male cats.

Procedures—Cats were randomly assigned to either a treatment or control group. Ocular infection with FHV-1 was induced (day 0) in all cats via inoculation of both eyes with 104 plaque-forming units of a plaque-purified FHV-1 field strain. Twice daily for 10 days beginning on day 4 after virus inoculation, the treatment group received 1 drop of 0.5% cidofovir in 1% carboxymethylcellulose in both eyes, and the control group received 1 drop of 1% carboxymethylcellulose in both eyes. A standardized scoring method was used to evaluate clinical signs of FHV-1 infection in each cat once daily for 24 days. The amount of ocular viral shedding was assessed by use of a quantitative real-time PCR procedure every 3 days during the study period. Clinical scores and viral quantification were averaged over the pretreatment (days 0 to 3), treatment (days 4 to 14), and posttreatment (days 15 to 24) periods for each cat.

Results—During the treatment period, clinical scores and amount of viral ocular shedding were significantly lower in the treatment group, compared with findings in the control group.

Conclusions and Clinical Relevance—Twice-daily application of 0.5% cidofovir solution in both eyes significantly decreased the amount of viral shedding and the severity of clinical disease in cats with experimentally induced ocular FHV-1 infection.

Abstract

Objective—To evaluate the efficacy of twice-daily ophthalmic application of 0.5% cidofovir solution in cats with experimentally induced primary ocular feline herpesvirus-1 (FHV-1) infection.

Animals—Twelve 6-month-old sexually intact male cats.

Procedures—Cats were randomly assigned to either a treatment or control group. Ocular infection with FHV-1 was induced (day 0) in all cats via inoculation of both eyes with 104 plaque-forming units of a plaque-purified FHV-1 field strain. Twice daily for 10 days beginning on day 4 after virus inoculation, the treatment group received 1 drop of 0.5% cidofovir in 1% carboxymethylcellulose in both eyes, and the control group received 1 drop of 1% carboxymethylcellulose in both eyes. A standardized scoring method was used to evaluate clinical signs of FHV-1 infection in each cat once daily for 24 days. The amount of ocular viral shedding was assessed by use of a quantitative real-time PCR procedure every 3 days during the study period. Clinical scores and viral quantification were averaged over the pretreatment (days 0 to 3), treatment (days 4 to 14), and posttreatment (days 15 to 24) periods for each cat.

Results—During the treatment period, clinical scores and amount of viral ocular shedding were significantly lower in the treatment group, compared with findings in the control group.

Conclusions and Clinical Relevance—Twice-daily application of 0.5% cidofovir solution in both eyes significantly decreased the amount of viral shedding and the severity of clinical disease in cats with experimentally induced ocular FHV-1 infection.

Contributor Notes

Dr. Fontenelle's present address is 6405 Tryon Rd, Ste 300, Cary, NC 27518.

Supported by a grant provided by the Morris Animal Foundation.

Dr. Radecki is a private statistical consultant at 150 N County Rd 3, Fort Collins, CO 80524.

The authors thank Jennifer Hawley for technical assistance and Dr. David Maggs for providing the feline herpesvirus-1 isolate.

Address correspondence to Dr. Powell.
  • 1.

    Nasisse MP, Guy JS, Davidson MG, et al. In vitro susceptibility of feline herpesvirus-1 to vidarabine, idoxuridine, trifluridine, acyclovir, or bromovinyldeoxyuridine. Am J Vet Res 1989;50:158160.

    • Search Google Scholar
    • Export Citation
  • 2.

    Nasisse MP, Davis BJ, Guy JS, et al. Isolation of feline herpesvirus 1 from the trigeminal ganglia of acutely and chronically infected cats. J Vet Intern Med 1992;6:102103.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Gaskell RM, Dennis PE, Goddard LE. Isolation of feline herpesvirus 1 from the trigeminal ganglia of latently infected cats. J Gen Virol 1985;66:391394.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    Ohmura Y, Ono E, Matsuura T, et al. Detection of feline herpesvirus 1 transcripts in trigeminal ganglia of latently infected cats. Arch Virol 1993;129:341347.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5.

    Gaskell RM, Povey RC. Experimental induction of feline viral rhinotracheitis re-excretion in FVR recovered cats. Vet Rec 1977;100:128133.

  • 6.

    Stiles J. Feline herpesvirus. Vet Clin North Am Small Anim Pract 2000;30:10011014.

  • 7.

    Burgesser KM, Hotaling S, Schiebel A, et al. Comparison of PCR, virus isolation, and indirect fluorescent antibody staining in the detection of naturally occurring feline herpesvirus infections. J Vet Diagn Invest 1999;11:122126.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8.

    Lappin MR, Andrews J, Simpson D, et al. Use of serologic tests to predict resistance to feline herpesvirus 1, feline calicivirus, and feline parvovirus infection in cats. J Am Vet Med Assoc 2002;220:3842.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9.

    Maggs DJ, Nasisse MP, Kass PH. Efficacy of oral supplementation with L-lysine in cats latently infected with feline herpesvirus. Am J Vet Res 2003;64:3742.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10.

    Stiles J, Townsend WM, Rogers QR, et al. Effect of oral administration of L-lysine on conjunctivitis caused by feline herpesvirus in cats. Am J Vet Res 2002;63:99103.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11.

    Kaufman HE, Varnell ED, Thompson HW. Trifluridine, cidofovir, and penciclovir in the treatment of experimental herpetic keratitis. Arch Ophthalmol 1998;116:777780.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12.

    Kaufman HE, Varnell ED, Thompson HW. Cidofovir and experimental herpetic stromal disease. Arch Ophthalmol 1999;117:925928.

  • 13.

    Hillenkamp J, Reinhard T, Ross RS, et al. The effects of cidofovir 1% with and without cyclosporin a 1% as a topical treatment of acute adenoviral keratoconjunctivitis: a controlled clinical pilot study. Ophthalmology 2002;109:845850.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 14.

    Hillenkamp J, Reinhard T, Ross RS, et al. Topical treatment of acute adenoviral keratoconjunctivitis with 0.2% cidofovir and 1% cyclosporine: a controlled clinical pilot study. Arch Ophthalmol 2001;119:14871491.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 15.

    Maggs DJ, Chang E, Nasisse MP, et al. Persistence of herpes simplex virus type 1 DNA in chronic conjunctival and eyelid lesions of mice. J Virol 1998;72:91669172.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 16.

    Vögtlin A, Fraefel C, Albini S, et al. Quantification of feline herpesvirus 1 DNA in ocular fluid samples of clinically diseased cats by real-time PCR. J Clin Microbiol 2002;40:519523.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 17.

    Leutenegger CM, Klein D, Hofmann-Lehmann R, et al. Rapid feline immunodeficiency virus provirus quantitation by polymerase chain reaction using the TaqMan fluorogenic real-time detection system. J Virol Methods 1999;78:105116.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 18.

    De Clercq E. Therapeutic potential of cidofovir (HPMPC, Vistide) for the treatment of DNA virus (ie herpes-, papova-, pox-, and adenovirus) infections. Verh K Acad Geneeskd Belg 1996;58:1947.

    • Search Google Scholar
    • Export Citation
  • 19.

    Maggs DJ, Clarke HE. In vitro efficacy of ganciclovir, cidofovir, penciclovir, foscarnet, idoxuridine, and acyclovir against feline herpesvirus type-1. Am J Vet Res 2004;65:399403.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 20.

    De Clercq E. Acyclic nucleoside phosphonates in chemotherapy of DNA virus and retrovirus infections. Intervirology 1997;40:295303.

  • 21.

    Romanowski EG, Bartels SP, Gordon YJ. Comparative antiviral efficacies of cidofovir, trifluridine, and acyclovir in the HSV-1 rabbit keratitis model. Invest Ophthalmol Vis Sci 1999;40:378384.

    • Search Google Scholar
    • Export Citation
  • 22.

    Owens JG, Nasisse MP, Tadepalli SM, et al. Pharmacokinetics of acyclovir in the cat. J Vet Pharmacol Ther 1996;19:488490.

  • 23.

    Nasisse MP, Dorman DC, Jamison KC, et al. Effects of valacyclovir in cats infected with feline herpesvirus 1. Am J Vet Res 1997;58:11411144.

    • Search Google Scholar
    • Export Citation
  • 24.

    Gordon YJ, Romanowski EG, Aroullo-Cruz T. Topical HPMPC inhibits adenovirus type 5 in the New Zealand rabbit ocular replication model. Invest Ophthalmol Vis Sci 1994;35:41354143.

    • Search Google Scholar
    • Export Citation
  • 25.

    Taskintuna I, Banker AS, Rao NA, et al. An animal model for cidofovir (HPMPC) toxicity: intraocular pressure and histopathologic effects. Exp Eye Res 1997;64:795806.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 26.

    Pavan-Langston DL, Dunkel EC. Antiviral drugs. In: Handbook of ocular drug therapy and ocular side effects of systemic drugs. Boston: Little Brown, 1991;159163.

    • Search Google Scholar
    • Export Citation
  • 27.

    Sherman MD, Feldman KA, Farahmand SM, et al. Treatment of conjunctival squamous cell carcinoma with topical cidofovir. Am J Ophthalmol 2002;134:432433.

    • Crossref
    • Search Google Scholar
    • Export Citation

Advertisement